An Open-Label, Multicentre, Observational, Post-Marketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients

Eun Yeong Cho, Jung Eun Cho, Eun Bin Lee, Seung Soo Yoo, Jung Hyun Chang

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Umeclidinium/vilanterol (UMEC/VI; ANORO ELLIPTA, GSK) is a commonly used dual bronchodilator. This study evaluated the safety and effectiveness of UMEC/VI in Korean patients with chronic obstructive pulmonary disease (COPD) over a 6-year period. Methods: This was an open-label, multicentre, observational, post-marketing surveillance study. A total of 3,375 patients were enrolled consecutively in 52 hospitals, by 53 physicians, between July 2014 and July 2020. Patients who were administered UMEC/ VI (fixed-dose 62.5 μg/25 μg) at least once and were monitored for safety and effectiveness were included in the analysis. Incidence and severity of adverse events (AEs) reported after administrating at least one dose of UMEC/VI were monitored, including unexpected adverse events (UAEs) and adverse drug reactions (ADRs). Effectiveness of UMEC/VI after 24 weeks of administration was also assessed using physician’s evaluation (effective, ineffective/no change, worsening, indeterminable) and lung function improvement. Results: Of 3,375 patients, 3,086 were included in the safety assessment group (mean age±standard deviation: 69.76±8.80 years; 85.9% male [n=2,652]; 73.1% aged ≥65 years [n=2,255]). The overall incidence of AEs was 28.8% (n=890), of which 2.2% (n=67) were ADRs. Serious AEs and UAEs were reported in 181 (5.9%) and 665 (21.6%) patients, respectively, and two patients (<0.1%) reported unexpected severe ADR. Of the 903/3,086 patients analysed for effectiveness, most (82.8%, n=748) showed overall disease improvement after UMEC/VI treatment. Conclusion: This study confirmed UMEC/VI administered to Korean patients according to the prescribing information was well-tolerated and can be considered an effective option for COPD treatment.

Original languageEnglish
Pages (from-to)33-46
Number of pages14
JournalTuberculosis and Respiratory Diseases
Volume86
Issue number1
DOIs
StatePublished - Jan 2023

Bibliographical note

Funding Information:
Editorial support for the development of this manuscript, under the direction of the authors, was provided by Rebecca Benatan, BSc, and Fiona Scott, Ph.D., of Ashfield MedComms, Macclesfield and Glasgow, UK, an Ashfield Health Company, and was funded by GSK. This study (204511) was funded by GSK. Trademarks are owned by or licensed to their respective owners (GSK [ANORO ELLIPTA]).

Funding Information:
This study (204511) was funded by GSK. Trademarks are owned by or licensed to their respective owners (GSK [ANORO ELLIPTA]).

Publisher Copyright:
Copyright © 2023 The Korean Academy of Tuberculosis and Respiratory Diseases.

Keywords

  • Chronic Obstructive
  • GSK573719
  • Postmarketing
  • Pulmonary Disease
  • Safety
  • Vilanterol

Fingerprint

Dive into the research topics of 'An Open-Label, Multicentre, Observational, Post-Marketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients'. Together they form a unique fingerprint.

Cite this